Methylated genes as new cancer biomarkers

MJ Duffy, R Napieralski, John Martens, PN Span, F Spyratos, FCGJ Sweep, N Brunner, John Foekens, M Schmitt

Research output: Contribution to journalArticleAcademicpeer-review

95 Citations (Scopus)

Abstract

Aberrant hypermethylation of promoter regions in specific genes is a key event in the formation and progression of cancer. In at least some situations, these aberrant alterations occur early in the formation of malignancy and appear to be tumour specific. Multiple reports have suggested that measurement of the methylation status of the promoter regions of specific genes can aid early detection of cancer, determine prognosis and predict therapy responses. Promising DNA methylation biomarkers include the use of methylated GSTP1 for aiding the early diagnosis of prostate cancer, methylated PITX2 for predicting outcome in lymph node-negative breast cancer patients and methylated MGMT in predicting benefit from alkylating agents in patients with glioblastomas. However, prior to clinical utilisation, these findings require validation in prospective clinical studies. Furthermore, assays for measuring gene methylation need to be standardised, simplified and evaluated in external quality assurance programmes. it is concluded that methylated genes have the potential to provide a new generation of cancer biomarkers. (C) 2008 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)335-346
Number of pages12
JournalEuropean Journal of Cancer
Volume45
Issue number3
DOIs
Publication statusPublished - 2009

Cite this